Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma

A Kamachi, M Munakata, Y Nasuhara, M Nishimura, Y Ohtsuka, M Amishima, T Takahashi, Y Homma, Y Kawakami

Abstract

Background—Goblet cell hyperplasia (GCH) is a prominent feature in animal models of atopic asthma produced by immunisation and following multiple challenges with antigens. The aim of this study was to examine the effect of a β2 agonist on the development of GCH induced by the immune response.

Methods—Brown Norway rats were immunised and challenged with an aerosol of ovalbumin for four weeks. Salbutamol (0.5 mg/kg/day) or vehicle was continuously delivered for the four weeks using a subcutaneously implanted osmotic minipump. The density of goblet cells, other morphological changes, and airway responsiveness to methacholine were evaluated 24 hours after the final challenge.

Results—Treatment with salbutamol induced a more than twofold increase in the mean (SE) number of goblet cells (53.7 (7.3) vs 114.5 (11.8) cells/104 epithelial cells, p<0.01) while it did not significantly influence airway wall thickening and eosinophilic infiltration. Airway responsiveness to methacholine required to generate a 50% increase in airway pressure (logPC150Mch) was also enhanced by the β2 agonist (−0.56 (0.21) vs −0.95 (0.05), p<0.05). Additional experiments revealed that the same dose of the β2 agonist alone did not cause GCH in non-immunised rats and that the enhancement of GCH by salbutamol was completely abolished by simultaneous treatment with methylprednisolone (0.5 mg/kg/day).

Conclusions—These data suggest that salbutamol enhances goblet cell hyperplasia and airway hyperresponsiveness in this rat model of atopic asthma.

Keywords: bronchial asthma; salbutamol; goblet cell hyperplasia

Goblet cell hyperplasia (GCH), an increase in the number of goblet cells in the airway epithelium, is a characteristic pathological change observed in bronchial asthma and chronic bronchitis. It has been repeated reported that marked GCH is a prominent feature in the airways. Immunisation and multiple challenges with some antigens induce marked GCH in animal models of atopic asthma. There is accumulating evidence that GCH is part of the phenotypic expression of atopic asthma because allergen induced inflammation responsible for atopic asthma is also considered to be involved in GCH. Indeed, interleukin (IL)-4 induces mucin gene expression and goblet cell metaplasia in vivo as well as in vitro. IL-13, another potential contributor to allergic asthma, leads to GCH in vivo. However, previous studies have shown that non-allergic stimuli such as cigarette smoke and sulphur dioxide can induce GCH in rat models. Furthermore, two early reports showed that β agonists such as isoprenaline can cause GCH and secretory gland hypertrophy in rats. Beta agonists are also known to cause enlargement of salivary glands in rats which is characterised by mitotic proliferation of the serous, mucous, and duct cells and associated with increased secretory activity.

The aim of this study was to examine the effect of the β2 agonist salbutamol on the development of GCH in a murine model of atopic asthma. We were specifically interested in the possible interactions between the β2 agonist and airway inflammatory responses in the development of GCH. Other morphological changes of the airways, including eosinophilic infiltration and the increase in wall thickness, were evaluated as well as airway responsiveness to methacholine.

Methods

ANIMALS AND IMMUNISATION

Specific pathogen-free six week old male Brown Norway rats (weight range 160–210 g) were purchased from Japan Charles River Co. The rats were kept in a conventional colony in a Hokkaido University animal care facility and allowed to feed and drink freely. They were actively immunised to ovalbumin (OA). They were first injected subcutaneously with 1 mg OA dissolved in gel containing 200 mg aluminium hydroxide. An adjuvant (1 ml) consisting of 102 heat killed Bordetella pertussis organisms was intraperitoneally injected at the same time. Two weeks after immunisation the rats inhaled 5% w/v OA for five minutes in an exposure chamber (35 × 25 × 20 cm) which allowed six animals to be put in at the same time. Identical challenges with inhaled OA were then repeated...
for the same rats every four days for the following four weeks. For inhalation challenge, OA was dissolved in saline and then aerosolised with an ultrasonic nebuliser (NE-U11B, Omuron Co, Tokyo, Japan) which delivered the aerosol at 1 ml/min.

**EXPERIMENTAL PROTOCOL**

Sham control (sham-cont) rats were initially injected with sterile saline instead of OA and then received repeated saline inhalation in the same manner. After four weeks of repeated inhalation challenge with OA or saline the airway responsiveness to methacholine was measured and histological analysis of the airways was performed on all animals. The experimental protocol is shown in fig 1.

In the first experiment the OA immunised rats were divided into three groups according to treatment during the period of inhalation challenge. Salbutamol (Sigma Chemical Co, St Louis, Missouri, USA), methylprednisolone (Sigma Chemical Co), or sterile saline was given during the four weeks using a subcutaneously implanted osmotic minipump (Alzet model 2ML4; Alza Co, Palo Alto, CA, USA) that allowed continuous delivery of the drug. These groups were called OA-cont, OA-salb, and OA-pred according to treatment.

For implantation of the pump four hours after the first inhalation challenge the rats were anaesthetised with an intraperitoneal injection of urethane (0.25 g/ml). A small incision was made at the surface between the scapulae to form a pocket in the subcutaneous connective tissue. The pump was inserted into the pocket and the incision was closed with sutures.

Salbutamol or methylprednisolone were dissolved in sterile saline with a concentration that maintained the administration rate at 0.5 mg/kg/day. To confirm whether a sufficient amount of salbutamol was delivered by the osmotic pump throughout the experiment the plasma concentration of salbutamol was measured by high pressure liquid chromatography on days 7 and 21 in two rats that received the drug in the same manner but without the aerosol challenge.18

Salbutamol markedly enhanced the development of GCH in the OA immunised rats in the first experiment so we then examined whether salbutamol alone could cause GCH in the non-immunised rats and also whether methylprednisolone could inhibit the enhancing effect of the β₂ agonist on GCH induced by the immune response. For this purpose the rats were divided into four groups: sham-cont, sham-salb, OA-salb, and OA-salb+pred. The former two groups did not receive immunisation and were treated either with sterile saline or salbutamol for the following four weeks as described in the first experiment. The other two groups received immunisation with OA and then were treated with salbutamol alone (0.5 mg/kg/day) or salbutamol and methylprednisolone (each at 0.5 mg/kg/day) delivered from the same osmotic minipump. In this second experiment aerosol was inhaled for 10 minutes at each challenge, twice as long as in the first experiment, to ensure sufficient exposure of the airway.

These experimental protocols and procedures were approved by the ethical committee on animal research, Hokkaido University School of Medicine.

**MEASUREMENT OF AIRWAY RESPONSIVENESS TO METHACHOLINE**

For the measurement of airway responsiveness to methacholine the rats were anaesthetised by intraperitoneal injection of pentobarbital sodium (50 mg/kg) 24 hours after the final challenge. A metallic tube of 2 mm internal diameter was inserted into the trachea. The rats were then mechanically ventilated with an animal ventilator (Rodent Ventilator Model 683, Harvard Apparatus Inc, Holliston, Massachusetts, USA) with a tidal volume of 6 ml/kg and frequency of 100 breaths/min. Airway opening pressure (Pao) was continuously measured through the side port of the tracheostomy tube by a pressure transducer (TP-603T, Nihon Kohden Co, Tokyo, Japan) and recorded on a polygraph for later analysis. After measurement of baseline Pao while the animals were inhaling physiological saline for one
minute, methacholine was given in progressively doubling doses from 0.0625 mg/ml for one minute at each dose until the Pao reached a plateau. The airway responsiveness to methacholine was assessed by the concentration of methacholine required to generate a 50% increase in Pao from the baseline level (PC_{150Mch}).

Figure 2  Degree of goblet cell hyperplasia according to treatment, expressed as the number of goblet cells/1000 epithelial cells of the large airways. sham-cont = sham control (n=5), OA-cont = ovalbumin control (n=5), OA-salb = ovalbumin + salbutamol (n=5), OA-pred = ovalbumin + methylprednisolone (n=4). All values are mean (SE). *p<0.01 compared with sham-cont, †p<0.01 compared with OA-cont. #p<0.01 compared with OA-salb and OA-pred.

Results

Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol

The number of goblet cells markedly increased in the OA-cont group compared with the sham-cont group (fig 2). Treatment with salbutamol induced an increase of more than twofold in the number of goblet cells compared with the sham-cont group, regardless of treatment with salbutamol. They were examined microscopically at a magnification of ×400 by an independent observer who was blind to any other data.

Epithelial cells containing abundant mucus stained pink or purple in their cytoplasm were identified as goblet cells. Total epithelial cells, including goblet cells, were counted for more than five large airways per section. We evaluated at least 200 consecutive epithelial cells lining the same airway not adjacent to lymphoid tissue. The density of goblet cells was expressed as the number of goblet cells/1000 epithelial cells, and this index was used for comparison between the groups.

The number of eosinophils in the submucosal area of the large airways was counted in H/E stained sections (five large airways per section, not adjacent to lymphoid tissue). Eosinophils were clearly identified by their eosin positive granules in the cytoplasm. Degranulated cells were not counted. The total number of eosinophils was divided by the length of the basement membrane measured using a computerised image analyser (XL10, Olympus Co, Tokyo, Japan) for comparisons between the groups.

Analysis of data

Statistical analysis of PC_{150} methacholine was performed on log transformed data. Comparisons of data between groups were performed using one way analysis of variance (ANOVA). As a post hoc test, means within the groups were compared by Fisher’s protected least significant difference procedure. Data are expressed as mean (SE); p values of <0.05 were considered significant.

Results

Numbers of goblet cells and eosinophils in the airways

The number of goblet cells markedly increased with multiple antigen challenges in the OA-cont group compared with the sham-cont group (fig 2). Treatment with salbutamol induced an increase of more than twofold in the number of goblet cells compared with the sham-cont group, regardless of treatment with salbutamol. They were examined microscopically at a magnification of ×400 by an independent observer who was blind to any other data.

Epithelial cells containing abundant mucus stained pink or purple in their cytoplasm were identified as goblet cells. Total epithelial cells, including goblet cells, were counted for more than five large airways per section. We evaluated at least 200 consecutive epithelial cells lining the same airway not adjacent to lymphoid tissue. The density of goblet cells was expressed as the number of goblet cells/1000 epithelial cells, and this index was used for comparison between the groups.

The number of eosinophils in the submucosal area of the large airways was counted in H/E stained sections (five large airways per section, not adjacent to lymphoid tissue). Eosinophils were clearly identified by their eosin positive granules in the cytoplasm. Degranulated cells were not counted. The total number of eosinophils was divided by the length of the basement membrane measured using a computerised image analyser (XL10, Olympus Co, Tokyo, Japan) for comparisons between the groups.

Analysis of data

Statistical analysis of PC_{150} methacholine was performed on log transformed data. Comparisons of data between groups were performed using one way analysis of variance (ANOVA). As a post hoc test, means within the groups were compared by Fisher’s protected least significant difference procedure. Data are expressed as mean (SE); p values of <0.05 were considered significant.

Results

Numbers of goblet cells and eosinophils in the airways

The number of goblet cells markedly increased with multiple antigen challenges in the OA-cont group compared with the sham-cont group (fig 2). Treatment with salbutamol induced an increase of more than twofold in the number of goblet cells compared with the sham-cont group.
Morphological changes of airway walls

The epithelial layer and the airway wall area significantly increased in the OA-cont group compared with the sham-cont group (fig 4). In contrast with GCH, however, the airway infiltration of eosinophils was not enhanced at all by treatment with salbutamol, although it was again completely inhibited by treatment with methylprednisolone (fig 4).

Airway responses to methacholine

As shown in fig 5, the airway responsiveness to methacholine was significantly increased in the OA-cont group compared with the sham-cont group and further enhanced in the OA-salb group compared with the OA-cont group. However, this airway hyperresponsiveness to methacholine was again completely inhibited by treatment with methylprednisolone.

Table 1 Morphological analysis of the large airways

<table>
<thead>
<tr>
<th>Group</th>
<th>ASM (×10⁻³)</th>
<th>AW (×10⁻³)</th>
<th>Epi (×10⁻³)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham-cont (n=5)</td>
<td>3.6 (0.2)</td>
<td>10.4 (1.0)</td>
<td>5.0 (0.4)</td>
</tr>
<tr>
<td>OA-cont (n=6)</td>
<td>3.3 (0.2)</td>
<td>14.2 (1.2)</td>
<td>7.2 (0.5)†</td>
</tr>
<tr>
<td>OA-salb (n=5)</td>
<td>2.9 (0.4)</td>
<td>13.1 (1.1)</td>
<td>7.4 (0.7)†</td>
</tr>
<tr>
<td>OA-pred (n=4)</td>
<td>3.3 (0.4)</td>
<td>12.0 (0.7)</td>
<td>6.3 (0.6)†</td>
</tr>
</tbody>
</table>

OA-cont group, while treatment with methylprednisolone completely inhibited GCH in antigen challenged rats. Typical pathological changes observed in these cases are shown in fig 3. The number of eosinophils in the airway walls also significantly increased in the OA-cont group compared with the sham-cont group (fig 4). In contrast with GCH, however, the airway infiltration of eosinophils was not enhanced at all by treatment with salbutamol, although it was again completely inhibited by treatment with methylprednisolone (fig 4).

Morphological changes of airway walls

The epithelial layer and the airway wall area significantly increased in the OA-cont group compared with the sham-cont group but the area of airway smooth muscle was unchanged (table 1). In rats treated with methylprednisolone none of the three indices changed significantly in comparison with the mean values of sham-cont rats (table 1).

Effects of salbutamol alone on GCH and of methylprednisolone on GCH observed in the OA-salb model

The same dose of salbutamol as was used in the first experiment (0.5 mg/kg/day) did not significantly enhance GCH in the non-immunised rats in the second experiment (fig 6). The number of goblet cells in sham-cont and OA-salb groups was larger than that observed in the first experiment. This may be explained by the difference in the exposure time to the aerosol between the two experiments (5 min vs 10 min) and by the difference in the body weights of the rats when killed (sham-cont 224 (7) g vs 288 (9) g; OA-salb 246 (7) g vs 280 (10) g, p<0.05 for both). Methylprednisolone completely abolished the enhancing effect of the β₂ agonist on GCH induced by the immune response observed in the first experiment.

Plasma concentration of salbutamol

The plasma concentration of salbutamol was 4.1 ng/ml on day 7 and 5.4 ng/ml on day 21 after the implantation of the osmotic mini-pump. These values are comparable to the therapeutic range for human subjects treated with 4 mg oral salbutamol every eight hours.

Discussion

In this study we have shown that OA sensitised rats had a more than twofold increase in the number of goblet cells after repeated challenges with OA for four weeks when treated with salbu-
Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol

It was not so prominent as that induced by iso-

In this rat model of atopic asthma, GCH could be produced in a rat model by sys-
temically administered drugs. They reported that both isoprenaline (a non selective β2 adrenergic agonist) and pilocarpine (a cholinergic agonist) increased the number of goblet cells and mucus secretion in the trachea and bronchial trees when given intravenously six times. The same group of investigators later reported that the selective β2 agonist salbuta-

mols was in the range of the therapeu-
tic dose for human diseases whereas in earlier studies doses more than 100 times higher were used. Indeed, the previous studies showed that the severity of GCH caused by isoprenaline or salbutamol was dependent on the dose and the injection frequency of these drugs. Secondly, salbutamol, a selective β2 adrenergic agonist, may not be as potent as a non-selective β agonist in inducing GCH when not given in combination with other inducers of GCH, as was the case in a previous study. Thirdly, the method of administration was different. We used an osmotic minipump for drug delivery which probably kept the plasma level of salbutamol stable throughout the experiment, while previous studies used repeated intra-

venous injections which are likely to have resulted in fluctuations in blood levels of the injected drug.

Of particular importance in this study was the fact that salbutamol, given in a clinically relevant dose, did not cause GCH in the non-immunised rats and markedly enhanced GCH in the Airways of the OA sensitised rats. It is beyond the scope of this study to investigate the mechanisms by which GCH is enhanced by the β2 agonist in multiple antigen challenged rats. However, there are several possible explanations.

Firstly, the β2 agonist may have direct or indirect enhancing effects on the immune mechanism responsible for the development of GCH. Several lines of evidence indicate that the development of GCH is mediated by Th2 cytokines such as IL-4 and IL-13. IL-4 induces mucin gene expression and GCH in vivo as well as in vitro. It has also been suggested that some immune mechanisms contribute to the development of GCH in a number of animal models of atopic asthma. Furthermore, a recent report indicated that the long term administration of a glucocorticoid of a β2 agonist may allow inhalation of larger amounts of antigens into the lungs because of its bronchodilating action, thus resulting in the enhancement of airway inflammation. We, however, consider this unlikely for two reasons: (1) there was no evidence of enhancement of airway inflamma-

tion by the long term administration of a β2 agonist. (2) There was no visible enhancement of GCH in the smaller Airways with the β2 agonist (data not shown).

Secondly, the method of administration was different. We used an osmotic minipump for drug delivery which probably kept the plasma level of salbutamol stable throughout the experiment, while previous studies used repeated intra-

venous injections which are likely to have
gested that β2 agonists could inhibit the release of IL-4 and IL-13 from antigen stimulated basophils by increasing the level of cyclic AMP. Reduction of the anti-inflammatory effects of the β2 agonist by downregulation or tachyphylaxis of its receptors after the administration of salbutamol may result in the exacerbation of airway inflammation followed by marked enhancement of GCH.

Finally, it must be noted that a non-β2 action of salbutamol might also be involved in the enhancement of GCH. We did not examine whether the effect of salbutamol on GCH was directly mediated by β2 adrenergic receptors.

In this study salbutamol caused significant enhancement of airway hyperresponsiveness to methacholine in addition to the development of GCH. This observation is consistent with some previous studies using animal models of atopic asthma.11–13 Both airway hyperresponsiveness and GCH are characteristic of bronchial asthma. It remains to be determined whether any common mechanisms exist between the two. One possibility is that GCH contributes to the enhancement of bronchial responsiveness to methacholine by changing epithelial barrier function. For instance, Yanta et al.1 showed that the number of secretory cells in the airways was positively correlated with airway hyperresponsiveness in dogs with naturally developing airway hyperresponsiveness. Alternatively, enhancement of airway inflammation by salbutamol, but not of eosinophilic infiltration, might have similarly influenced airway hyperresponsiveness and GCH in this study.

In conclusion, we have shown in this study that salbutamol, in a clinically relevant dose, has the potential to enhance GCH and airway hyperresponsiveness to methacholine in a rat model of atopic asthma when systemically and continuously administered using an osmotic pump. Since such enhancement of GCH did not occur with the same dose of salbutamol when given to non-immunised rats, we conclude that the β2 agonist enhances GCH induced by the immune response and that this can be completely abolished by simultaneous treatment with glucocorticoids. Although it may be premature to suppose that this phenomenon is applicable to humans, one should keep in mind the possibility that regular use of β2 agonists may exacerbate GCH and the resulting mucus hypersecretion in patients with bronchial asthma. Further study of the mechanisms of this phenomenon might provide insights into the roles of β2 agonists and glucocorticoids in the treatment of bronchial asthma in humans.